EN DE
Watch MeiraGTx Holdings PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MeiraGTx Holdings PLC (MGTX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of MeiraGTx Holdings PLC stock $8.04, price $9.62, that is 16.4% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN KYG596651029

MH MeiraGTx Holdings PLC logo Thin data Nov 10, 2026

MeiraGTx Holdings PLC

MGTX · US
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Solidly profitable · 19.9% net margin (TTM)
Ranks above peers (7/9)
Revenue last quarter +86% vs. a year ago.
Mixed Growth (revenue 5y +39.2 %/yr in USD)
Negative equity (buybacks among others)
Moderate moat 52/100
Insiders sold $3.4M (6M)
Fair value $8.04 · Overvalued
Quality 34/100
Negative free cash flow
Thin data
Estimate
Watch MeiraGTx Holdings PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.74 $3.60 Fair Value $8.04 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $3.60 – $23.74 · fair‑value band $6.03 – $10.05 · the $9.62 price screens above the $8.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow MeiraGTx Holdings in your weekly email

Every Wednesday you see whether MeiraGTx Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

Show moreShow less

The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration.

Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain.

The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system.

MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Stock analysis

MeiraGTx Holdings PLC (MGTX) currently trades at $9.62, while our estimate is $8.04, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $6.03 (bear) to $10.05 (bull), the price of $9.62 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

MeiraGTx Holdings PLC reported revenue of $81.4M in FY2025 versus $37.7M in FY2021, a compound +21.2%/yr. Reported net income was −$114M in FY2025.

Key figures

Market cap $902M Small · P/E ratio 11.1 · P/S ratio 2.27 · EPS (TTM) $0.8700 · Net margin 19.9% · Return on equity 72.2% · Return on assets (EBIT) −41.1% (5-year average) · Operating margin 76.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).

What moves the price

The share trades about 36% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, MGTX screens richer than that median.

Fair Value

Bear $6.03 Fair Value $8.04 Bull $10.05
Price $9.62 · Downside -16.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 18
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 30
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 30
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 41
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $3.4M and none bought.

  • SaleRichard GirouxCFO & COO3× since Apr 21, 2026: 168,000 shares, avg. $10.89$1.8MOct 20, 202610b5-1 plan
  • SaleStuart NaylorCHIEF SCI OFCR, OPHTHALMOLOGY3× since Apr 7, 2026: 82,979 shares, avg. $11.60$962,669Oct 6, 202610b5-1 plan
  • SaleAlexandria ForbesPRESIDENT & CEO, Director3× since Mar 24, 2026: 186,000 shares, avg. $10.15$1.9MAug 18, 202610b5-1 plan

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+144.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−401.9% (2020) → −130.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MGTX screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare MeiraGTx Holdings PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 7/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −16.4% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −46.7% · Below median
Net margin (12 months) 19.9% · Top 25%
Operating margin (12 months) 76.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 86.1% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 11.1× · Cheapest 25%
P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 2.27× · Cheapest 25%
EV/EBITDA 4.5× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs MGTX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs MGTX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs MGTX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs MGTX
argenx SE ARGX $971.55 $908.40 −7% vs MGTX
CSL Limited CSL A$201.68 A$181.40 −10% vs MGTX
Moderna, Inc MRNA $250.83 $158.70 −37% vs MGTX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs MGTX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs MGTX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs MGTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MeiraGTx Holdings PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MeiraGTx Holdings PLC Fair Value". https://www.fairvalue-calculator.com/stock/MGTX

Frequently asked questions

Is MeiraGTx Holdings PLC (MGTX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $8.04 versus a price of $9.62, about 16% lower (overvalued).
What is the fair value of MGTX?
Our estimate for MeiraGTx Holdings PLC is $8.04 (as of Nov 10, 2026), built from audited fundamentals. The current price: $9.62.
What is the quality score of MGTX?
MeiraGTx Holdings PLC has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MeiraGTx Holdings PLC (MGTX)?
Our calculated price target is the estimate of $8.04 (as of Nov 10, 2026). Cautious scenario $6.03, optimistic scenario $10.05. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the MeiraGTx Holdings PLC stock forecast for 2026?
Our estimate puts fair value at $8.04, about 16% lower versus a price of $9.62 (overvalued). Cautious scenario $6.03, optimistic scenario $10.05. The calculation is refreshed regularly with new filings.
What is the intrinsic value of MeiraGTx Holdings PLC (MGTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MeiraGTx Holdings PLC it is $8.04 per share (as of Nov 10, 2026), against a price of $9.62.
Is MeiraGTx Holdings PLC stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MGTX trades above its calculated fair value: price $9.62, fair value $8.04, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MGTX?
No. The price is what the market pays today ($9.62); the fair value is what the company's own numbers justify ($8.04). For MeiraGTx Holdings PLC the two are $1.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is MeiraGTx Holdings PLC worth?
The market values MeiraGTx Holdings PLC at about $902M (market capitalisation, as of Nov 10, 2026). Per share that is $9.62; our models calculate a fair value of $8.04 per share.
What do the bullish and bearish scenarios say about MGTX?
Our models span a range for MeiraGTx Holdings PLC: cautious scenario $6.03, base $8.04, optimistic $10.05 per share (as of Nov 10, 2026, price $9.62). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MGTX?
MeiraGTx Holdings PLC trades at a price-to-earnings ratio of 11.1 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $8.04 is built from several models across several years. Other multiples: P/S 2.3, EV/EBITDA 4.5.
How solid is the balance sheet of MeiraGTx Holdings PLC (MGTX)?
Balance-sheet figures for MeiraGTx Holdings PLC (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is MGTX from its 52-week high?
MeiraGTx Holdings PLC trades at $9.62, about 36% below its 52-week high of $14.97 and 38% above the low of $6.99 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $8.04 is for.
Which stocks are comparable to MeiraGTx Holdings PLC?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MeiraGTx Holdings PLC stock attractive at the current price?
The data as of Nov 10, 2026: price $9.62, calculated fair value $8.04 (−16%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. MeiraGTx Holdings PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MeiraGTx Holdings PLC (MGTX)?
The closing price on Nov 10, 2026 was $9.62. Our estimate is $8.04, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MeiraGTx Holdings PLC right now?
Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of MeiraGTx Holdings PLC

How large is the market capitalisation of MeiraGTx Holdings PLC (MGTX)?
The market capitalisation of MeiraGTx Holdings PLC is $902M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MeiraGTx Holdings PLC (MGTX)?
The price-to-sales ratio of MeiraGTx Holdings PLC is 2.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MeiraGTx Holdings PLC (MGTX)?
Earnings per share at MeiraGTx Holdings PLC are $0.8700 (price ÷ EPS = P/E 11.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MeiraGTx Holdings PLC (MGTX)?
The net margin of MeiraGTx Holdings PLC is 19.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MeiraGTx Holdings PLC (MGTX)?
The return on equity (ROE) of MeiraGTx Holdings PLC is 72.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MeiraGTx Holdings PLC (MGTX)?
On an EBIT basis the return on assets of MeiraGTx Holdings PLC is −41.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MeiraGTx Holdings PLC (MGTX)?
The operating margin of MeiraGTx Holdings PLC is 76.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MeiraGTx Holdings PLC (MGTX)?
Revenue at MeiraGTx Holdings PLC is growing +86.1% versus a year earlier (3y avg +72.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MeiraGTx Holdings PLC (MGTX) generate?
The free cash flow of MeiraGTx Holdings PLC is −$50.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MeiraGTx Holdings PLC (MGTX) carry?
The net debt of MeiraGTx Holdings PLC is $22.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MeiraGTx Holdings PLC in the live analysis

One click puts MeiraGTx Holdings PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.